How did CTKB's Q1 2025 EPS forecast compare to past trends?

Cytek Biosciences (CTKB) is forecasted to have an EPS of -$0.05 in Q1 2025, which is an improvement compared to the -$0.02 EPS reported in Q1 2023. However, when compared to Q1 2024, the -$0.05 EPS represents a decline from the -$0.02 EPS reported in that quarter. This indicates a challenging trend for CTKB's earnings in the near term, with a deterioration in the latest quarter's performance compared to the previous year's same period.

CTKB Diluted EPS YoY, Diluted EPS